Outcomes of primary refractory multiple myeloma and the impact of novel therapies

Over the past decade, use of novel agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has resulted in high response rates and improvement in overall survival (OS) for patients with multiple myeloma (MM); however, the prognostic significance of refractoriness to these ag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Majithia, Neil, Rajkumar, S. Vincent, Lacy, Martha Q., Buadi, Francis K., Dispenzieri, Angela, Gertz, Morie A., Hayman, Suzanne R., Dingli, David, Kapoor, Prashant, Hwa, Lisa, Lust, John A., Russell, Stephen J., Go, Ronald S., Kyle, Robert A., Kumar, Shaji K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801545/
https://ncbi.nlm.nih.gov/pubmed/26214732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24131
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados